{"ticker": {"uuid": "db0619a2-8b22-46b5-b1c2-d87efbe31ea2", "symbol": "190A", "name": "CHORDIA THERAPEUTICS INC", "exchange": "JPX", "country": "JP", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Perspective Therapeutics Announces Acceptance of VMT-\u03b1-NET Data for Oral Presentation at the ESMO Congress 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/perspective-therapeutics-announces-acceptance-vmt-162200065.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T16:22:00+00:00", "published_display": "17 Jul 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chordia Therapeutics Wins AMED Grant for Advanced Cancer Research with Kyoto University", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQWlhYUlduR28xOEE3YmJJZGZwcDNKVTFuUEtPeE5XRl9EdVZiRFJKOUMyXzFnbjhhXzNzbmhfaUJZTFJ4T1V2NWJ3Y194RUdicGRab1B2YWVublRnZXFsb3ZrSHkxU0hEVU5oZTJZQkZkTjJza0hVUGg5VHFyVmd2M0JSb1hJRnEwNEJ2UV9fbzI0aWl3V2hlQWZ2VFZNTS1mSnNDdHZaMzdMWWFXb0hyRWZVU3dxSEIyNi1IUG8tLXp3a2t2UlJYbkFWNHAwTWotT2VLV3RR?oc=5", "source_name": "TipRanks", "published_at": "2026-07-17T09:47:36+00:00", "published_display": "17 Jul 2026 09:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Q&A session at end] Chordia Therapeutics to report interim U.S. trial results for rogocekib in mid-2026, targeting marketing approval filing by end of 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5jcVhsTU9RTnZBbkxEVDVMUE1QclVBb1pVUnNTSkp6cm4zOGlFQ1RhS0ZnNTA5LXo0cDd1dndqSFFBckE2NVYyUVFFRFk4VExndHVjNW5n?oc=5", "source_name": "\u30ed\u30b0\u30df\u30fcFinance", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Perspective Therapeutics Announces Acceptance of VMT-\u03b1-NET Data for Oral Presentation at the ESMO Congress 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/perspective-therapeutics-announces-acceptance-vmt-162200065.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T16:22:00+00:00", "published_display": "17 Jul 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chordia Therapeutics Wins AMED Grant for Advanced Cancer Research with Kyoto University", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQWlhYUlduR28xOEE3YmJJZGZwcDNKVTFuUEtPeE5XRl9EdVZiRFJKOUMyXzFnbjhhXzNzbmhfaUJZTFJ4T1V2NWJ3Y194RUdicGRab1B2YWVublRnZXFsb3ZrSHkxU0hEVU5oZTJZQkZkTjJza0hVUGg5VHFyVmd2M0JSb1hJRnEwNEJ2UV9fbzI0aWl3V2hlQWZ2VFZNTS1mSnNDdHZaMzdMWWFXb0hyRWZVU3dxSEIyNi1IUG8tLXp3a2t2UlJYbkFWNHAwTWotT2VLV3RR?oc=5", "source_name": "TipRanks", "published_at": "2026-07-17T09:47:36+00:00", "published_display": "17 Jul 2026 09:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Q&A session at end] Chordia Therapeutics to report interim U.S. trial results for rogocekib in mid-2026, targeting marketing approval filing by end of 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5jcVhsTU9RTnZBbkxEVDVMUE1QclVBb1pVUnNTSkp6cm4zOGlFQ1RhS0ZnNTA5LXo0cDd1dndqSFFBckE2NVYyUVFFRFk4VExndHVjNW5n?oc=5", "source_name": "\u30ed\u30b0\u30df\u30fcFinance", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 71, "total_relevant": 3, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 3, "score": 50, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 66, "events": [{"event": "general", "label": "Market update", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 82.0, "latest_week": "2026-07-10", "one_week_move": 2.5, "four_week_move": -15.5, "twelve_week_move": -42.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.203509, "market_dynamics_buy_signal": false, "relative_strength": -52.68335, "fair_value_gap": -63.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 36.2402, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.5% over one week, -15.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "\u30ed\u30b0\u30df\u30fcFinance", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 2}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "66/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.5% over one week, -15.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Perspective Therapeutics Announces Acceptance of VMT-\u03b1-NET Data for Oral Presentation at the ESMO Congress 2026"}], "updated_at": "2026-07-17T16:30:24.482468+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}